Combination chemo-immunotherapy in advanced oesophageal squamous cell carcinoma

Affiliations

Comment

Katrin Marie Sjoquist. Lancet Oncol. 2023 May.

. 2023 May;24(5):419-420.

doi: 10.1016/S1470-2045(23)00151-1. Epub 2023 Apr 17.

¹ NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW 1450, Australia. Electronic address: katrin.sjoquist@sydney.edu.au.

No abstract available

Conflict of interest statement

I declare no competing interests.

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang J, Wu X, Yao Y, Shen L, Kojima T, Gotovkin E, Ishihara R, Wyrwicz L, Van Cutsem E, Jimenez-Fonseca P, Lin CY, Wang L, Shi J, Li L, Yoon HH. Xu J, et al. Lancet Oncol. 2023 May;24(5):483-495. doi: 10.1016/S1470-2045(23)00108-0. Epub 2023 Apr 17. Lancet Oncol. 2023. PMID: 37080222 Clinical Trial.